FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Malik Rajesh
2. Issuer Name and Ticker or Trading Symbol

G1 Therapeutics, Inc. [ GTHX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

700 PARK OFFICES DRIVE, SUITE 200
3. Date of Earliest Transaction (MM/DD/YYYY)

5/10/2021
(Street)

RESEARCH TRIANGLE PARK, NC 27709
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/10/2021  M  10000.00 A$0.30 53300.00 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $0.30 5/10/2021  M     10000.00   (2)2/27/2025 Common Stock 10000.00 $0.00 65000.00 D  

Explanation of Responses:
(1) Represents 42,300 shares of common stock and 11,000 restricted stock units
(2) All shares underlying this option have vested.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Malik Rajesh
700 PARK OFFICES DRIVE, SUITE 200
RESEARCH TRIANGLE PARK, NC 27709


Chief Medical Officer

Signatures
/s/ James Stillman Hanson, attorney-in-fact5/11/2021
**Signature of Reporting PersonDate

G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more G1 Therapeutics Charts.
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more G1 Therapeutics Charts.